Acute Hepatitis C: Current Status and Future Perspectives.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Hepatitis C*/drug therapy ; Hepatitis C*/epidemiology ; Hepatitis C*/virology ; Antiviral Agents*/therapeutic use ; Hepacivirus*/drug effects ; Hepacivirus*/physiology ; Hepacivirus*/genetics; Humans ; Risk Factors ; Acute Disease

The hepatitis C virus (HCV) infection continues to represent a significant public health threat and is a leading cause of liver cirrhosis, liver cancer, and liver-related mortality. The World Health Organization (WHO) has set a goal for 2030: to eliminate HCV infection as a public health threat by reducing new HCV infections by 90% and mortality by 65%. The early phase of HCV infection represents a pivotal point in the evolution of hepatitis C. Despite a favourable course in the majority of patients, approximately 50-70% of individuals with recently acquired hepatitis C will develop a chronic infection, defined as the persistence of viremia for a period exceeding six months. The diagnosis and treatment of a recent HCV infection should facilitate engagement in multidisciplinary care, prevent the development and complications of chronic liver disease, and reduce ongoing transmission in key populations. Therefore, early treatment in the early phase of infection compared with deferring treatment until the chronic infection remains a valid approach in the era of direct antiviral agents (DAAs). This approach is supported by a cost-effectiveness analysis. The aim of this review is to synthesise the existing knowledge on the early phase of hepatitis C virus infection, with a particular focus on the current risk factors, natural history, therapeutic management, and future perspectives.

Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. (PMID: 35180382)
Hepatology. 2014 Jun;59(6):2101-9. (PMID: 24442928)
Lancet HIV. 2022 Jun;9(6):e414-e427. (PMID: 35659336)
Hepatology. 2018 Mar;67(3):837-846. (PMID: 29059461)
Transplantation. 1997 Dec 27;64(12):1775-80. (PMID: 9422419)
J Hepatol. 2020 Nov;73(5):1170-1218. (PMID: 32956768)
Int J STD AIDS. 2017 Feb;28(2):145-159. (PMID: 26826159)
Clin Infect Dis. 2019 Jul 18;69(3):514-522. (PMID: 31220220)
Clin Infect Dis. 2023 May 25;:. (PMID: 37229695)
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S238-S244. (PMID: 37579203)
Viruses. 2024 Jul 11;16(7):. (PMID: 39066277)
Hepatology. 2020 Jul;72(1):7-18. (PMID: 31652357)
AIDS. 2015 Nov;29(17):2335-45. (PMID: 26258525)
N Engl J Med. 2021 Feb 11;384(6):541-549. (PMID: 33567193)
Vaccines (Basel). 2020 Feb 17;8(1):. (PMID: 32079254)
Lancet Infect Dis. 2017 Feb;17(2):215-222. (PMID: 28029529)
Hepatology. 2022 Oct;76(4):1190-1202. (PMID: 35313015)
Clin Infect Dis. 2012 Nov 15;55(10):1408-16. (PMID: 22893583)
Dig Liver Dis. 2010 Feb;42(2):81-91. (PMID: 19748329)
J Hepatol. 2021 Oct;75(4):829-839. (PMID: 34023350)
Gastroenterology. 2003 Jul;125(1):80-8. (PMID: 12851873)
N Engl J Med. 2001 Nov 15;345(20):1452-7. (PMID: 11794193)
J Hepatol. 2014 Nov;61(1 Suppl):S34-44. (PMID: 25443345)
JHEP Rep. 2022 Dec 16;5(3):100650. (PMID: 36852107)
Lancet Infect Dis. 2013 Jun;13(6):497-506. (PMID: 23523674)
Clin Infect Dis. 2017 Apr 01;64(7):860-869. (PMID: 28362947)
JHEP Rep. 2023 Jul 27;5(10):100867. (PMID: 37771545)
Cells. 2019 Apr 25;8(4):. (PMID: 31027278)
J Infect Dis. 2000 May;181(5):1528-36. (PMID: 10823750)
Lancet. 1995 Oct 14;346(8981):1006-7. (PMID: 7475549)
Clin Mol Hepatol. 2023 Jul;29(3):623-642. (PMID: 36800699)
Dig Liver Dis. 2003 Feb;35(2):104-13. (PMID: 12747629)
Gastroenterology. 1999 Oct;117(4):933-41. (PMID: 10500077)
Nat Med. 2000 May;6(5):578-82. (PMID: 10802716)
AIDS. 2009 Jan 2;23(1):89-93. (PMID: 19050390)
Intervirology. 2005;48(4):213-5. (PMID: 15920344)
Vaccine. 2010 Aug 31;28(38):6367-73. (PMID: 20619382)
N Engl J Med. 2011 Jun 23;364(25):2429-38. (PMID: 21696309)
Lancet Gastroenterol Hepatol. 2017 May;2(5):347-353. (PMID: 28397698)
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. (PMID: 35595834)

Keywords: DAA therapy; early phase of infection; hepatitis C virus; modes of transmission; natural history

0 (Antiviral Agents)

Date Created: 20241127 Date Completed: 20241127 Latest Revision: 20241130

20241202

PMC11599108

10.3390/v16111739

39599853